Cylomox

Founder

Bader Alahmari, MBBS, MSCI
KAIMRC

Co-Founder

Reid Rubsamen MD, MS, MHCM
CEO, Flow Pharma, Inc.

Team Member

Julie Lang, MD
Cleveland Clinic

Cancer Vaccines: The Next Big Thing in Immunotherapy

The novel FlowVax cancer vaccine immunotherapy allows cancers to be treated by teaching the patient's immune system to attack only tumor cells, leaving healthy cells undamaged. The patented FlowVax platform uses tiny beads called microspheres, the same size as white blood cells, to deliver manufactured tumor markers that killer T-cells learn to attack after the FlowVax microspheres are naturally processed by the patient's immune system.

Download PDF

Value Proposition

Preclinical data for FlowVax has shown it to be safe and able to treat an aggressive breast cancer tumor in mice that does not express PD-L1. FlowVax therefore is positioned to treat tumors which do not express PD-L1 and are therefore not addressable by Keytruda.

FlowVax Annual Revenue 15% of non PD-L1 Patients

Market Projection

Using conservative assumptions:

1 approval/year over 8 years
15% of TAM patients treated
21,000 patients/year at year 8
$75K revenue per patient treated
$24B USD total revenue by year 8

References

Harris, P.E., Rubsamen, R. New Vaccine Therapy for Triple-Negative Breast Cancer. Curr Breast Cancer Rep 16, 288–301 (2024)
Wright S, et al. Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications. Int. J. Mol. Sci. 2023, 24, 11827
Burkholz SR, et al. Survivin (BIRC5) Pepitide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Vaccines 2023 11(3)